Type 2 diabetes
Conditions
Interventions
A :10 cases ate resistant starch rice, then ate reference food common rice.
B:10 cases ate reference food common rice, then ate resistant starch rice.
Sponsors
The Third Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Type 2 diabetes patients aged 18-65 with stable condition (HbA1c < 9%, GLU < 16.7 mmol/L); 2. BMI within 18.5~24.0kg/m²; 3. No history of food allergy, intolerance and blood phobia; 4. No drugs affecting glucose tolerance have been taken in the past 3 months. Oral stable-dose contraceptives, acetylsalicylic acid, thyroxine, vitamin and mineral supplements, or medications for hypertension or osteoporosis are acceptable; 5. Be able to tolerate fasting for at least 10 hours; 6. Be able to understand and abide by the test operation process, voluntarily participate in the test, and be able to sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with primary renal diabetes, diabetes caused by pancreatic damage and secondary diabetes (such as Cushing's syndrome or diabetes caused by acromegaly); 2. Serious diabetic complications (kidney, retina, nerve, vascular lesions, etc.), and anything that the researchers consider it is not suitable to participate in this study; 3. Have used other drugs that may affect blood glucose metabolism within 2 months before screening, including but not limited to systemic corticosteroids (topical or ophthalmic, nasal spray or inhalation, except for intra-articular injection), growth hormone, etc.; 4. Any of the followings: 1) Decompensated heart failure (NYHA class grade III or IV), unstable angina, myocardial infarction, coronary history of arterial bypass grafting or coronary stenting, uncontrolled or severe serious arrhythmia (such as long QT syndrome, etc.), hemorrhagic stroke moderate or ischemic stroke within 6 months prior to screening; 2) Diabetic ketoacidosis or diabetic hyperosmolar coma within 6 months before screening; 3) Urinary system/reproductive system infection occurred within 6 months before screening; 4) Suffering from acute infection or serious illness that affects blood glucose control within 1 month before screening; 5) Currently suffering from severe peripheral arterial disease; 6) Any disease that may cause hemolysis or red blood cell instability that affects HbA1c detection (such as hemolytic anemia, etc.); 7) Uncontrolled hypertension (SBP = 160mmHg and/or DBP = 100mmHg); 8) Uncontrolled thyroid dysfunction (stable controlled is defined as having received a stable dose of thyroid hormone replacement or antithyroid drug therapy for at least 3 months and thyroid function within the normal range); 9) Combined with other endocrine system diseases, such as multiple endocrine neoplasia; 10) Severe osteoporosis; 11) History of acute or chronic pancreatitis; 12) Suffering from severe gastrointestinal diseases that affect drug absorption, distribution, metabolism, and excretion disease, or have undergone gastrointestinal surgery that affects drug absorption (such as gastrointestinal stoma anastomosis or bowel resection, etc.); 13) Have a history of malignant tumors within 5 years (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix), or currently have potential malignant tumors; 5. Have participated in or are participating in any other experimental drug treatment within 3 months before screening (refers to being randomized or receiving experimental drugs); 6. Severe mental illness or language barrier, unwilling or unable to fully understand and cooperate; 7. Pregnant and lactating women; 8. Other circumstances that the researchers consider are not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The fluctuation range of postprandial plasma glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| The fluctuation range of postprandial lipids;The fluctuation range of postprandial insulin;The fluctuation range of uricemia;The fluctuation range of CRP; | — |
Countries
China
Contacts
Public ContactChenzhong Li
The Third Affiliated Hospital of Southern Medical University
Outcome results
None listed